Parkinson’s disease (PD) is a progressive neurodegenerative synucleinopathy. Clinical diagnosis is based on the presence of motor symptoms, including bradykinesia, rigidity, rest tremor, and postural instability. Although the cause of PD is still unknown, the severe nigro-striatal dopamine loss provides the basis for dopaminergic treatment of motor symptoms. Non-motor symptoms are also prominent, probably reflecting more widespread degenerative changes in PD, and include autonomic, enteric, and neuropsychiatric symptoms. Neuropsychiatric symptoms can be prominent, such as anxiety, depression, psychosis, sleep disturbances, and cognitive impairment. This has suggested to some that PD may be accurately described as a neuropsychiatric disease rather than a pure movement disorder.

Prevalence and Incidence
The prevalence of hallucinations in PD in cross-sectional prospective studies varies widely, from 16 % to 75 % (see Table 1). In a Norwegian population-based prevalence cohort study, 230 patients with PD were followed up prospectively for 12 years. The point prevalence of PDP was 17.8 % (41/230) at baseline and increased to 48 % (12/25) at the 12-year visit. Over the course of the study nearly two-thirds of patients (60 %, 137 patients) had developed PDP during the course of their disease. The incidence rate of PDP was 79.7 per 1,000 person-years.

The variation in the reported prevalence of PDP may be due to differences in study design and patient selection, as well as inconsistencies in screening and patient or caregiver under-reporting. Patients may conceal their psychosis symptoms because of stigma associated with psychiatric disease, and fear of psychiatric hospitalization or long-term care placement. Caregivers may be unaware of mild symptoms.
Parkinson’s Disease

Table 1: Prevalence of Hallucinations in Parkinson’s Disease as Reported in Cross-sectional Prospective Studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>n</th>
<th>Total Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Williams et al., 2007</td>
<td>115</td>
<td>75</td>
</tr>
<tr>
<td>Pacchetti et al., 2003</td>
<td>289</td>
<td>30</td>
</tr>
<tr>
<td>Paleau et al., 2005</td>
<td>274</td>
<td>32</td>
</tr>
<tr>
<td>Bailéd et al., 2002</td>
<td>152</td>
<td>23</td>
</tr>
<tr>
<td>Schrag et al., 2002</td>
<td>124</td>
<td>23</td>
</tr>
<tr>
<td>Fénelon et al., 2000</td>
<td>216</td>
<td>40</td>
</tr>
<tr>
<td>Aarsland et al., 1999</td>
<td>235</td>
<td>16</td>
</tr>
<tr>
<td>Inslerberg et al., 1998</td>
<td>121</td>
<td>37</td>
</tr>
<tr>
<td>Graham et al., 1997</td>
<td>129</td>
<td>25</td>
</tr>
<tr>
<td>Sanchez-Ramos et al., 1996</td>
<td>214</td>
<td>26</td>
</tr>
</tbody>
</table>

Studies used a questionnaire on hallucinations, with the exception of Aarsland et al., in which section I of the Unified Parkinson’s Disease Rating Scale was used. *Patients from movement disorders clinics; Patients from hospitals or private clinics; Population-based study. Source: Fénelon, 2008.*

Figure 1: Systems and Mechanisms Implicated in the Genesis of Visual Hallucinations in Parkinson’s Disease

![Visual Hierarchy Diagram]

- Monoaminergic and cholinergic projection systems
- Pharmacologic agents
- Sleep/wake and dream mechanism
- Visual pathways
- 5-HT = serotonin; ACh = acetylcholine; DA = dopamine; H = visual hallucinations.


- Physicians and other providers may be hesitant to query symptoms of psychosis.
- Retained insight can make PDP symptoms seem mild and nontroublesome.
- Cognitive impairment may impede evaluation of psychosis symptoms.

For all of these reasons, PDP is probably under-recognized. 2 Overall, this delay in recognizing PDP can lead to symptoms becoming severe before a diagnosis of PDP is made. 2,7,10,11

Risk Factors and Emergence of Parkinson’s Disease Psychosis

The risk for developing PDP can be influenced by both endogenous and exogenous factors. Endogenous risk factors implicated in PDP include advanced age, severity of PD, duration of PD, depression, cognitive impairment, and sleep disturbances. 2,4,12,13 Exogenous factors may trigger PDP to emerge, or may worsen mild or subclinical PDP. These can include systemic disorders, including urinary tract (or other) infections, dehydration, fever, and medications. Both dopaminergic and anticholinergic medications increase the risk for PDP. Indeed, medications used to treat the motor systems of PD may also trigger and/or increase PDP symptoms, including levodopa. 2 As PD advances levodopa dosage tends to increase, with an increased risk for PDP. Other medications commonly used to treat PD motor systems may also increase PDP, especially dopamine agonists, selegiline, amantadine, and anticholinergics. 13

PDP is often thought of as a side effect of dopaminergic therapy. 14 Increasing evidence, however, suggests that PDP is a manifestation of the underlying neurodegeneration of PD and is related to progression of the underlying disease. 12,14 Dosage and duration of dopamine replacement therapy have not been consistently correlated with PDP. 12,13,14 In an evaluation of 422 patients with PD and hallucinations, drug treatment was not identified as a risk factor for emergence of hallucinations in PD. 13 In addition, in a community-based study of 245 patients with PD, anti-parkinsonian drug therapy was not shown to be associated with psychosis. 4 In a study evaluating intravenous levodopa in patients with PDP, visual hallucinations did not appear to correlate with higher plasma levodopa nor to sudden changes in plasma levodopa levels. 13 A proposed pathophysiologic diagram of hallucinations in PD is provided (see Figure 1).

Symptoms

Visual hallucinations are the most common symptoms of PDP. 7,14,18,19 Cognitive impairment and/or dementia are independent risk factors for hallucinations, and the prevalence of hallucinations is higher in PD patients with dementia than in PD patients without dementia. 5,6,20 PDP tends to develop in parallel with dementia, but can also herald cognitive impairment. 7,4 Visual hallucinations are often preceded by sleep disturbances, vivid dreams, or REM sleep behavior disorder. 21

While most hallucinations in PDP are visual, as PDP progresses, auditory, tactile, gustatory, and olfactory hallucinations can also occur. 1,3,11 Hallucinations can occur at any time of day but are more frequent in the evening and at night. 14 Older patients may be more likely to have nonvisual or mixed hallucinations than hallucinations that are purely visual in nature. 22

Visual hallucinations include passage hallucinations (brief visions of a person, or more commonly an animal, passing sideways) and presence hallucinations (sensation of somebody’s presence when, in fact, no person is there). 2,7,14 More complex visual hallucinations can occur, consisting of one or more people, who may or may not be familiar, and may be living, or deceased. Also, visual hallucinations can be of animals, children, or objects. 5 Illusions are misinterpretations of a real external, essentially visual stimulus, for example, seeing a tree as a person or patterns on carpets as if they are moving. 7,9,14

PDP involves a spectrum of symptoms that extends beyond formed visual hallucinations and illusions. The content of delusions is commonly paranoid, often centered on beliefs of infidelity and abandonment. 11,14,20 Delusions in patients with PDP may involve family members, which can add to the stress experienced by the family. 11 Frégoli syndrome 23 (a rare disorder in which a person holds a belief that different people are in fact a single person who changes their appearance or is in disguise), and Capgras syndrome 24 (a delusion that someone has been replaced by an
identical-looking impostor) have also been reported in the course of PDP, particularly in PD patients with dementia.

PDP is typically progressive over time, both in frequency and severity. Early symptoms of PDP have sometimes been considered as ‘benign’ since insight is often retained. However, in many patients who initially have insight into their hallucinations, insight is lost as the disease progresses. The likelihood that mild hallucinations will not increase in severity and/or frequency is low, frequently increasing within 2–3 years. Nonvisual hallucinations also occur and can complicate management. Even “benign,” relatively minor psychotic symptoms can negatively impact quality of life and PD patients with hallucinations have been associated with depression and anxiety, even when insight is retained. As PDP progresses, delusions and paranoia can emerge, and these symptoms may become more troublesome, when accompanied by agitation.

Recognition and Evaluation

Consensus diagnostic criteria for PDP have been outlined by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Mental Health (NIMH) Work Group (see Table 2). The NINDS–NIMH criteria describe a chronic course of clinical features occurring with a clear sensorium and reflect the clinical, temporal, and progressive characteristics of PDP. According to the NIND–NIMH criteria, the diagnosis of PDP requires at least one of the following: illusions, false sense of presence, hallucinations, or delusions. These features should occur following PD onset and should be present for at least 1 month, either as recurrent or continuous symptoms, excluding other causes (dementia or other psychiatric disorders such as schizophrenia or bipolar disorder) and noting associated features, such as the presence or absence of insight, dementia, and PD treatments. PDP prevalence depends in part on the operational definitions employed. When the NINDS–NIMH criteria, which include minor symptoms, were applied to a cross-sectional cohort of patients with PD, the prevalence of PDP (previously defined by the presence of hallucinations and/or delusions) rose from 43% to 60%. PDP does not appear to be associated with age of PD onset or dosage of dopaminergic medication. In one study, emergence of PDP occurred >5.5 years from PD diagnosis.

Routine evaluation for the emergence of PDP symptoms is an important aspect of the routine care of patients with PD. It is important to have an open and ongoing dialogue about potential PDP symptoms with the patient and their caregiver(s) and this can help to overcome the stigma associated with psychosis and the potential under-reporting of early PDP symptoms. Evaluation for the presence of PDP symptoms should be routinely queried at clinic visits. Common symptoms to query may include illusions; visual and other hallucinations; paranoia and other delusions; and false sense of presence or passage. If PDP is uncovered, it is important to define symptom onset, duration (recurrent or continuous for 1 month), insight, cognition, medications being taken, and to exclude other systemic causes. Initially, symptoms tend to occur intermittently with varying frequency, and can increase from several times a month to multiple times a day. PDP symptoms will often recur and/or worsen over time. The persistence and progression of symptoms thus require regular monitoring.

Table 2: Proposed Diagnostic Criteria for Parkinson’s Disease Psychosis

<table>
<thead>
<tr>
<th>1. Characteristic symptom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of at least one of the following:</td>
</tr>
<tr>
<td>• Illusions</td>
</tr>
<tr>
<td>• False sense of presence</td>
</tr>
<tr>
<td>• Hallucinations</td>
</tr>
<tr>
<td>• Delusions</td>
</tr>
</tbody>
</table>

2. Primary diagnosis

3. Chronology of the onset of psychosis symptoms

4. Duration

The symptoms(s) in criterion 1 are recurrent or continuous for 1 month

5. Exclusion of other causes

The symptoms in criterion 1 are not accounted for better by another cause of Parkinsonism such as dementia with Lewy bodies, psychiatric disorders (e.g. schizophrenia, schizoaffective disorder, or bipolar disorder), or a general mood condition including delirium

6. Associated features

• With/without insight
• With/without dementia
• With/without treatment for PD

As defined by the National Institute of Neurological Disorders and the National Institutes of Mental Health Work Group. PD = Parkinson’s disease. Source: Ravina et al., 2007.

Caregiver Burden

Caring for a person with PD is largely carried out by informal caregivers, such as spouses. Psychosis symptoms in PD are a strong predictor of increased caregiver burden. As PDP progresses, the impact on the caregiver’s social activities, emotional and physical health, and overall level of stress increases. PDP progression and caregiver burden are both independent risk factors as well as leading causes for long-term care placement. Patients placed in a nursing home because of their PDP symptoms are likely to remain there permanently and have a higher mortality rate.

A cross-sectional, population-based study in Norway was carried out in 94 caregivers of patients with PD who were living at home. This study identified mental symptoms as the most consistent and powerful predictors of caregiver distress, which suggests that identification and treatment of mental symptoms may reduce the distress experienced by caregivers. In a 4-year, prospective, population-based study of 178 community-dwelling individuals with PD, also conducted in Norway, the presence of hallucinations emerged as the strongest predictor of institutionalization.

Summary and Management Challenges

PDP is a frequent but under-recognized nonmotor complication in PD, with more than 50% of patients with PD expected to develop psychosis at some time. This contributes significantly to diminished quality and activities of patient and caregiver daily life, and an increased risk for morbidity, and long-term care placement. Further, the presence of psychotic symptoms has been shown to be an independent predictor of mortality in PD. A better understanding of what causes PDP is emerging, and suggests that the effects of the underlying disease on dopaminergic, serotonergic, and/or cholinergic pathways may be a major contributor to PDP, which can be triggered by dopaminergic medications and other...
Parkinson’s Disease

exogenous factors. Routine evaluation of PDP symptoms by treating clinicians is important to try to reduce the impact of undetected PDP on patients and their caregivers.

Once detected, PDP-management strategies should initially focus on minimizing potential offending medications and treating any systemic triggers. Approaches that reduce dopaminergic therapies though may result in suboptimal motor control, perhaps with increasing fall risk. If cognitive status is preserved, deep brain stimulation may have a role in providing motor control while allowing a reduction in medication. Although currently there are no FDA-approved medications for PD psychosis treatment, atypical antipsychotics are sometimes used but may worsen motor function. Physicians should also discuss PDP with patients/caregivers earlier in the course of treating PD to help improve recognition that PDP is rather common throughout the course of PD.

47. Schrag A, Ben-Shlomo Y, Quin N. How common are complications of Parkinson’s disease? J Neurol. 2002;249:419–23.